IPSEN, OOO

Stroke affects over 12 million globally, with 100 million living with its effects. Advances in care lead to survival but bring complications like spasticity and cognitive issues, causing socio-economic burdens. Early intervention and rehabilitation improve outcomes, reduce long-term complications, and lower healthcare costs. Prompt treatment, especially for spasticity, significantly reduces overall costs. Public healthcare aims to reduce stroke care burden, minimizing readmissions and supporting caregivers. Investing in early post-stroke care improves patient outcomes and caregiver well-being, advocating for timely care and rehabilitation policies.

The FDA identified additional safety concerns with Ocaliva, used to treat primary biliary cholangitis, including serious liver injury in non-cirrhotic patients. Since 2021, 20 more liver-related events were reported. The FDA advises frequent liver tests and discontinuation if disease progresses or if the drug is ineffective. Ocaliva, once a blockbuster prospect, faces setbacks with FDA rejections and competition from new drugs.

Nuvalent appoints Grant Bogle to its Board of Directors, enhancing its transition from development to commercialization of novel kinase inhibitors, with pivotal data expected in 2025.

EFPIA highlights EU's roadmap for precision oncology to address rising cancer burden, despite forecasted mortality rate declines. Stakeholder roundtable in Brussels aims to improve personalized cancer treatment. EU initiatives, including AI-powered cancer care and the DigiONE pilot, aim to advance precision medicine. A gold-standard cancer data management system is necessary for innovative precision medicine access, emphasizing standardized data formats, robust privacy, and professional education.

Ipsen to pay $610m for Biomunex's preclinical MAIT cell engager BMx-502, targeting GPC3 on solid tumors. MAIT cells, without CD3 receptors, avoid cytokine release syndrome, enhancing therapeutic index. Ipsen will handle clinical development and commercialization, with Biomunex completing IND-enabling package.

T.C. has consulted/advised/spoken for ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, Targeted Oncology. W.N.W.Jr. has consulted/advised/spoken for Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda, United Medical.

Ipsen secures global rights for BMX-502, a novel T cell engager targeting MAIT cells and GPC3 tumor antigen, developed by Biomunex using BiXAb technology, with potential to treat solid tumors and overcome limitations of current TCE therapies.

Neuroendocrine Tumors Market to grow at 5.1% CAGR (2020-2034) driven by upcoming therapies, rising incident cases, and increased research. Key players include Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size in 6MM.